The association of probiotics with mechanical debridement has been proposed for the treatment of periodontal diseases, but this effect has not yet been evaluated in patients with type 2 diabetes mellitus (DM2). Being the main objective of periodontal therapy associated or not to adjuvants reduce the inflammation and the restoration of a tissue homeostasis, is this et al. in 2008, proposed an index, called PISA, to evaluate an area and inflamed tissue. On the other hand, it is also important to analyze how dental care impacts on the quality of life of individuals. Among several instruments to measure the quality of life of oral health, Oral Health Impact Profile (OHIP-14) (Slade 97) has been shown to be efficient through the evaluation of associations with sociodemographic and clinical variables with oral status. The objective of this randomized, triple-blind, controlled clinical trial will be to evaluate the effects of probiotic administration (Lactobacillus reuteri) as adjunctive therapy in the treatment of periodontitis associated with T2DM. Patients will also respond to the OHIP questionnaire 14 on quality of life. Participants will be randomized into 2 groups: Test Group (n = 20): Patients with periodontitis and patients with DM2 who will receive periodontal debridement associated with the probiotic Lactobacillus reuteri; and Control Group (n = 20): patients with Periodontitis and patients with DM2, treated with periodontal debridement associated with a placebo. The results obtained before and after the periodontal therapy will be analyzed through the Shapiro-wilk and Chi-Square test.
News published in Agência FAPESP Newsletter about the scholarship: